Inmune Bio Secures Favorable Patentability Opinion for CORDStrom™

An update from Inmune Bio ( (INMB) ) is now available.

On April 16, 2025, INmune Bio Inc. announced receiving a favorable patentability opinion from the United States Patent and Trademark Office for its CORDStrom™ platform, a next-generation mesenchymal stromal cell product. This development marks a significant milestone, potentially enhancing the company’s intellectual property exclusivity until 2045 and accelerating the U.S. national application process. The favorable opinion follows promising Phase 2 trial results, indicating CORDStrom™’s potential in reducing pain and improving skin conditions, which could unlock substantial therapeutic and commercial opportunities.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Inmune Bio’s overall stock score reflects significant financial challenges, including declining revenue and ongoing losses. Technical indicators show potential downward momentum, while valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

To see Spark’s full report on INMB stock, click here.

More about Inmune Bio

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases. The company operates three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, the Natural Killer Cell Priming Platform, and the CORDStrom™ platform, which utilizes human umbilical cord-derived mesenchymal stromal cells for treating inflammatory and degenerative diseases.

YTD Price Performance: 51.52%

Average Trading Volume: 347,173

Technical Sentiment Signal: Buy

Current Market Cap: $173.4M

For a thorough assessment of INMB stock, go to TipRanks’ Stock Analysis page.